Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
MWN-AI** Summary
Celularity Inc. (Nasdaq: CELU), a leader in regenerative and cellular medicine with a focus on longevity science, has announced a significant strategic partnership aimed at monetizing its placental-derived biomaterials portfolio. This deal, expected to close by April 15, 2026, could generate up to $35 million in upfront payments and milestone-based revenues, providing non-dilutive capital that will further strengthen the company’s financial position.
Under the arrangement, Celularity has granted exclusive licensing rights for its commercial-stage biomaterials and select development-stage programs. Notably, the company will retain exclusive manufacturing rights and continue to generate revenue through its FDA-compliant facility in Florham Park, New Jersey, which positions it favorably in the biomaterials market. This partnership allows Celularity to streamline its efforts towards developing its longevity-focused therapeutic pipeline while ensuring ongoing revenue from the manufacturing of licensed products.
To support this strategic pivot, Celularity is undergoing an organizational realignment that will reduce operating costs and better align resources with its core focus on longevity therapeutics. This restructuring will involve transitioning personnel connected with the biomaterials activities to the commercial partner and reducing its workforce as necessary to enhance operational efficiency.
Celularity aims to intensify development efforts on placental-derived cell therapies targeting the biological drivers of aging, such as cellular senescence and chronic inflammation. The company is gearing up to explore new commercial and clinical opportunities in states like Florida, Texas, and Arizona, where regulations allow for investigational uses of cellular technologies.
In summary, this strategic partnership not only enhances Celularity’s capital efficiency but also refines its focus on pioneering innovative solutions within the longevity medicine space.
MWN-AI** Analysis
Celularity Inc. (Nasdaq: CELU) has recently secured a pivotal strategic license deal worth up to $35 million, focused on enhancing its longevity-focused strategy while optimizing its capital position. As the transaction is expected to close by mid-April 2026, investors should closely monitor its implications for Celularity’s financial health and strategic direction.
The licensing agreement allows Celularity to monetize its biomaterials portfolio while refocusing on its core therapeutic developments. The immediate benefits of the deal include non-dilutive capital and royalties from future sales, enhancing liquidity without increasing shareholder dilution. This financial strategy aligns with the company's goal to streamline operations and invest in high-potential longevity therapeutics, thereby reducing operating complexities while retaining a stream of manufacturing revenue.
The organizational realignment will also likely lower operating expenses, further strengthening the company’s bottom line. By transitioning personnel to the commercial partner, Celularity can concentrate its resources where they matter most—on developing innovative therapies targeting aging’s biological drivers. The emphasis on longevity science, addressing conditions such as chronic inflammation and tissue degeneration, positions Celularity well in a high-growth sector as global interest in regenerative medicine gains traction.
Investors should consider the potential for increased market demand for regenerative therapies, especially in states like Florida, Texas, and Arizona, where investigational use pathways are expanding. Celularity’s ability to explore these markets while advancing its developmental programs could catalyze significant appreciation in its stock value.
Given these dynamics, existing shareholders may view the current price levels as a buying opportunity, while potential investors might explore entry points around this transformative initiative. Nonetheless, keeping an eye on regulatory developments and execution risks will be essential in assessing the viability of Celularity’s long-term strategic vision.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Transaction expected to generate up to $35 million in upfront and milestone payments
- Celularity retains exclusive manufacturing rights, creating continued biomaterials revenue and margin opportunity
- Organizational realignment reduces operating expenses and sharpens focus on longevity therapeutics
FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on longevity science, today announced that it has entered into definitive agreements establishing a strategic commercialization partnership for its placental-derived biomaterials portfolio. The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions.
The transaction is intended to monetize Celularity’s commercial biomaterials portfolio while allowing the Company to concentrate resources on advancing its longevity-focused therapeutic pipeline.
Under the terms of the agreements, Celularity granted an exclusive license to its commercial-stage biomaterials portfolio and certain development-stage programs. The Company expects to receive upfront consideration at closing and may receive additional milestone-based payments totaling up to $35 million, representing non-dilutive capital. Celularity will also be eligible to receive royalties on future net sales of certain development-stage products upon commercialization.
Celularity will act as the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey, creating an ongoing manufacturing revenue stream while maintaining participation in the economics of the licensed products. The Company’s vertically integrated manufacturing infrastructure is designed to support scalable, quality-driven production for both commercial-stage products and next-generation placental-derived cellular therapeutics.
“This partnership represents a disciplined step forward in strengthening our capital position while sharpening our focus on longevity medicine, a broad set of applications where Celularity’s proprietary, newborn placental cellular technology has significant biological advantages,” said Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer. “We are monetizing commercial infrastructure in a capital-efficient manner, reducing operating complexity, and retaining long-term economic participation through manufacturing and royalties. This transaction enhances our ability to concentrate resources on high-value cellular therapeutics targeting the fundamental mechanisms of aging.”
pH Partners, LLC acted as financial advisor to Celularity in connection with the transaction.
Organizational Realignment and Capital Efficiency
As part of the transaction, personnel associated with the Company’s commercial and product development biomaterials activities are expected to transition to the commercial partner at closing. Celularity will further reduce its workforce in line with the organizational restructuring, which is designed to lower operating expenses and align resources with Celularity’s core longevity-focused therapeutic pipeline and scalable manufacturing platform. This realignment is expected to enhance capital efficiency by concentrating investment on high-value clinical and manufacturing initiatives while reducing non-core operating expenditures.
Strategic Focus on Longevity
Following the transaction, Celularity will intensify its longevity focus on developing placental-derived cell therapies designed to address key biological drivers of aging, including cellular senescence, chronic inflammation, and tissue degeneration. The Company also intends to expand its commercial and clinical opportunities in jurisdictions that permit investigational use of cellular and biologic technologies under applicable state frameworks, including Florida, Texas, and Arizona, among others, in compliance with applicable law and regulatory requirements.
Dr. Hariri added, “We believe longevity medicine represents a significant long-term opportunity where we can lead. Emerging investigational use pathways may allow physicians and researchers to responsibly evaluate innovative biologic technologies and explore the regenerative potential of placental-derived cell therapies while Celularity continues advancing its regulated development programs.”
About Celularity
Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity leverages the placenta’s unique biology, immunologic properties, and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease.
For more information, please visit www.celularity.com.
Forward-Looking Statements
Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the anticipated closing of the strategic commercialization partnership described herein and the expected timing thereof; the potential receipt of upfront consideration, milestone payments, royalties and manufacturing revenues associated with the transaction; the anticipated operational and strategic benefits of the partnership; Celularity’s strategic focus on longevity science, scalable manufacturing infrastructure and capital efficiency; the continued development, regulatory advancement and commercialization of the licensed biomaterials portfolio and development-stage programs; and Celularity’s plans to pursue commercial and clinical opportunities for its technologies in jurisdictions that permit investigational use under applicable law.
Forward-looking statements are based on Celularity’s current expectations and assumptions regarding future events and are subject to risks, uncertainties and changes in circumstances that are difficult to predict. Words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “will,” and similar expressions are intended to identify forward-looking statements.
Actual results may differ materially from those expressed or implied in forward-looking statements as a result of various risks and uncertainties, including, without limitation, the ability of the parties to satisfy closing conditions and complete the transaction on the anticipated timeline or at all; the ability to realize anticipated financial benefits of the transaction, including milestone payments, royalties or manufacturing revenues; variability in manufacturing volumes or product demand; regulatory developments affecting the development, manufacture or commercialization of Celularity’s products; the successful execution of Celularity’s strategic realignment and organizational restructuring; the development and commercialization of Celularity’s longevity-focused therapeutic programs; and the other risks and uncertainties described under the caption “Risk Factors” in Celularity’s Annual Report on Form 10-K and Form 10-K/A for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on May 8, 2025, and May 21, 2025, respectively, and in Celularity’s other filings with the SEC.
Forward-looking statements speak only as of the date of this press release. Except as required by law, Celularity undertakes no obligation to update or revise any forward-looking statements contained herein to reflect events or circumstances occurring after the date of this press release.
Investor Contact
Carlos Ramirez
Senior Vice President, Celularity Inc.
Carlos.ramirez@celularity.com
FAQ**
How does the expected monetization of Celularity's biomaterials portfolio through this partnership impact the future value of Celularity Inc. Warrant CELUW in terms of market perception and investor confidence?
Considering the organizational realignment to focus on longevity therapeutics, how might this strategic shift affect the long-term performance and potential profitability of Celularity Inc. Warrant CELUW?
What specific milestones are tied to the anticipated $million in payments, and how do these milestones influence the valuation and trading prospects of Celularity Inc. Warrant CELUW in the coming quarters?
With Celularity retaining exclusive manufacturing rights and potential royalties, how can this sustainable revenue model enhance the growth narrative for investors holding Celularity Inc. Warrant CELUW?
**MWN-AI FAQ is based on asking OpenAI questions about Celularity Inc. (NASDAQ: CELU).
NASDAQ: CELU
CELU Trading
-1.48% G/L:
$1.33 Last:
85,034 Volume:
$1.24 Open:
